Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 2, 2010, Pages 103-109

  Kwak, Hyun Hee ^a,b   Shim, Won Sik ^b   Son, Mi Kyung ^a   Kim, Yoon Ji ^a   Kim, Tae Hyoung ^a   Youn, Hyun Jun ^a   Kang, Soo Hyoung ^a   Shim, Chang Koo ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Exenatide; GLP 1 agonist; Poly(d,l lactide co glycolide); Sustained release formulation; Type 2 diabetes mellitus; Zucker diabetic fatty (ZDF) rats

Indexed keywords

ANTIDIABETIC AGENT; DA 3091; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; MICROSPHERE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEEDING BEHAVIOR; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; MALE; MICROSPHERES; PEPTIDES; RATS; RATS, ZUCKER; VENOMS;

EID: 77952240728     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.006     Document Type: Article

References (24)

1. Agerso H., Jensen L.B., Elbrond B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
2. Clark J.B., Palmer C.J., Shaw W.N. The diabetic Zucker fatty rat (41611). Proc. Soc. Exp. Biol. Med. 1983, 73:68-75.
3. Corsetti J.P., Sparks J.D., Peterson R.G., Smith R.L., Sparks C.E. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000, 148:231-241.
4. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
5. Del Prato S., Felton A.M., Munro N., Nesto R., Zimmet P., Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int. J. Clin. Pract. 2005, 59:1345-1355.
6. Drucker D.J. The biology of incretin hormones. Cell. Metab. 2006, 3:153-165.
7. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
8. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
9. Efendic S., Alvarsson M., Brismar K., Wagner H. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. Acta Physiol. (Oxford) 2008, 192:117-125.
10. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267:7402-7405.
11. Etgen G.J., Oldham B.A. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 2000, 49:684-688.
12. Gedulin B.R., Smith P., Prickett K.S., Tryon M., Barnhill S., Reynolds J., Nielsen L.L., Parkes D.G., Young A.A. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005, 48:1380-1385.
13. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics 1984, Lea & Febiger, Philadelphia, pp. 17-28.
14. m glucose transporters in non-insulin-dependent diabetes. Science 1990, 250:546-549.
15. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
16. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 2008, 60:470-512.
17. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., Baron A.D. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health. Syst. Pharm. 2005, 62:173-181.
18. Kwak H.H., Shim W.S., Hwang S.M., Son M.K., Kim Y.J., Kim T.H., Yoon Z.H., Youn H.J., Lee G.I., Kang S.H., Shim C.K. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm. Res. 2009, 26:2504-2512.
19. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Pept. 2004, 117:77-88.
20. Peterson R.G., Shaw W.N., Neel M.A., Little L.A., Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News 1990, 32:16-19.
21. Riddle M.C. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol. Metab. Clin. North Am. 2005, 34:77-98.
22. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
23. Wright, S.G., Christenson, T., Yeah, T.Y., Rickey, M.E., Hotz, J.M., Kumar, R., Costantino, H.R., 2008. Polymer-based sustained release device, Alkermes, Inc. (Cambridge, MA, US), US Patent 7,456,254B2.
24. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.